Vertex Pharmaceuticals Inc. closed $45.72 below its 52-week high ($510.64), which the company achieved on August 1st.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

The FDA should have more big news for Vertex only a few weeks later. It expects to announce an approval decision on ...

This was the stock's second consecutive day of losses.

Investing in biotech stocks isn't for everyone. An unsuccessful clinical trial can cause a huge decline. The competition is ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $508.38, a high estimate of ...

In a report released today, Brian Abrahams from RBC Capital maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report), ...

According to Benzinga Pro, Vertex Pharmaceuticals's peer group average for short interest as a percentage of float is 6.15%, ...

Vertex Pharmaceuticals (VRTX) closed at $489.43 in the latest trading session, marking a +0.84% move from the prior day.

Really excited to have another year of it. My name is Olivia Brayer. I'm a senior Biotech Analyst here at Cantor. And we're really excited to have the Vertex IR team with us. We have Susie Lisa who is ...

Vertex said sickle cell patients had not yet received infusions of its gene therapy Casgevy. That’s now changed, as the ...

Three Motley Fool contributors think they've identified dirt-cheap healthcare stocks to buy right now. Here's why they picked CRISPR Therapeutics (NASDAQ: CRSP), Gilead Sciences (NASDAQ: GILD), and ...